Akebia Therapeutics, Inc. announced the completion of an End of Dispute Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss its upcoming resubmission of its New Drug Application for vadadustat, a treatment for anemia due to chronic kidney disease in adults on dialysis. The resubmission is expected by the end of the third quarter of 2023.